Jefferies Group’s TG Therapeutics TGTX Stock Holding History

Jefferies Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-75,000	Closed	-$1.19M	–	2373
2014 Q4	$1.19M	Buy	+75,000	New	+$977K	0.01%	909

Other funds holding TGTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Group's TGTX Position: Q2 2019 in Review

Jefferies Group sold out of TG Therapeutics (TGTX) in Q2 2019, closing a stake of 10,664 shares — an estimated $86K sold.

Jefferies Group first reported a position in TGTX in Q2 2015 and held it in 5 quarters. The position peaked at $143K in Q4 2018. 116 funds tracked by Wall St. Rank hold TGTX as of Q2 2019.

Jefferies Group reported no remaining TG Therapeutics position as of Q2 2019 after selling out during the quarter.
Jefferies Group sold 10,664 TG Therapeutics shares in Q2 2019, an estimated $86K.
Jefferies Group first reported a position in TG Therapeutics in Q2 2015 and held it in 5 quarters.
Jefferies Group's TG Therapeutics position peaked at $143K in Q4 2018.
116 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2019.

Based on Jefferies Group's 13F filing for Q2 2019, filed 14 Aug 2019.